Evidence map›Paper›PMID 32461723›Full record

ArticleInterdisciplinary toxicology2019

The effect of venlafaxine on blood pressure and ECG in rats fed with high-fat-fructose diet.

Michaela Sasváriová, Dominika Micháliková, Barbara Tyukos Kaprinay, Lazaros Salvaras, Slavomila Hričáková, Vladimír Knezl, Zdenka Gáspárová, Tatiana Stankovičová

Open access · diamondAbstract read
In one paragraph

Article in Interdisciplinary toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Antidepressant Augmentation of Antipsychotic Treatment in Schizophrenia: A Narrative Review.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Michaela SasváriováDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Slovakia.
Dominika MichálikováInstitute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine of the Slovak Academy of Sciences, Bratislava, Slovakia.
Barbara Tyukos KaprinayInstitute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine of the Slovak Academy of Sciences, Bratislava, Slovakia.
Lazaros SalvarasDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Slovakia.
Slavomila HričákováDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Slovakia.
Vladimír KnezlInstitute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine of the Slovak Academy of Sciences, Bratislava, Slovakia.
Zdenka GáspárováInstitute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine of the Slovak Academy of Sciences, Bratislava, Slovakia.
Tatiana StankovičováDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Slovakia.
Comenius University Bratislava · SKSlovak Academy of Sciences · SKCentre of Experimental Medicine of the Slovak Academy of Sciences · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic syndrome represents one of the major health, social and economic issues nowadays, and affects more than 25% people worldwide. Being a multifactorial health problem, metabolic syndrome clusters various features, such as obesity, dyslipidemia, hyperglycemia and hypertension. Each of these disturbances represents a risk factor for developing cardiovascular disease. Moreover, patients with metabolic syndrome are more likely to suffer from depression, thus treatment with antidepressants (

Indexed as

antidepressantsblood pressureECGhigh-fat-fructose dietmetabolic syndromevenlafaxine

Identifiers

PMID32461723
PMCPMC7247368
OpenAlexW3030203494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.